Holen Sie sich die Stockscreener-App
25.43
0.22%
-16.29
Schlusskurs vom Vortag:
$9.14
Offen:
$25.38
24-Stunden-Volumen:
5,554
Relative Volume:
66.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-13.53
EPS:
-1.88
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
-2.04%
6M Leistung:
+10.95%
1J Leistung:
-15.87%
1-Tages-Spanne:
$25.32
$25.50
1-Wochen-Bereich:
$25.32
$25.50
52-Wochen-Spanne:
$25.32
$25.50
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Firmenname
Flexion Therapeutics, Inc.
Sektor
Telefon
781-305-7777
Adresse
10 Mall Road, Suite 301, Burlington
Compare FLXN vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
25.43 | 0 | 0 | 0 | 0 | 0.00 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.08 | 58.26B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.93 | 54.44B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.61 | 48.41B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.28 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
498.65 | 22.12B | 3.13B | 1.27B | 1.12B | 26.39 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-08-20 | Eingeleitet | Goldman | Neutral |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-29 | Eingeleitet | Credit Suisse | Outperform |
| 2020-06-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2019-12-27 | Bestätigt | The Benchmark Company | Buy |
| 2019-12-05 | Eingeleitet | Craig Hallum | Buy |
| 2019-11-25 | Eingeleitet | BTIG Research | Buy |
| 2019-05-09 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2019-01-04 | Bestätigt | Needham | Buy |
| 2019-01-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2018-06-28 | Eingeleitet | The Benchmark Company | Buy |
| 2017-10-09 | Bestätigt | Needham | Buy |
| 2017-08-24 | Eingeleitet | Northland Capital | Outperform |
| 2016-12-22 | Eingeleitet | Raymond James | Strong Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-07-21 | Eingeleitet | Lake Street | Buy |
| 2016-05-03 | Fortgesetzt | Wells Fargo | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-09-09 | Bestätigt | Needham | Buy |
Alle ansehen
Flexion Therapeutics, Inc. Aktie (FLXN) Neueste Nachrichten
Joint Pain Injections Market Overview and Leading Players: - openPR.com
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz
Flexion Therapeutics, Inc.Common Stock (NQ: FLXN - FinancialContent
Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (... - ADVFN
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates - ADVFN
Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release... - ADVFN
Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (... - ADVFN
Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research
Anti-Inflammatory Therapeutics Market Size to Hit USD 164.44 Bn by 2035 - Precedence Research
Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Globe and Mail
Musculoskeletal Pain Treatment Market Size (7MM) is expected to grow at a significant CAGR by 2034, estimates DelveInsight - The Globe and Mail
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - pharmiweb.com
Musculoskeletal Pain Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight - openPR.com
Osteoarthritis Gene Therapy Market Research Report 2025 - InsightAce Analytic
Knee Osteoarthritis Pipeline Drugs Insights Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight - The Globe and Mail
Knee Osteoarthritis Pipeline Drugs Insights Report 2025: - openPR.com
Swollen Knee Treatment Market Expands as Demand for Non-Invasive Therapies Accelerates Globally - newstrail.com
Cipher Mining Inc.Common Stock (NQ: CIFR - FinancialContent
Knee osteoarthritis Market: Epidemiology, Therapies, Companies, DelveInsight | Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics - Barchart.com
Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight - The Globe and Mail
Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma
Non-Opioid Pain Treatment Market Size, Share | CAGR Of 8.1% - Market.us
High Costs of Knee Osteoarthritis Treatment - Market.us
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Flexion Therapeutics (NASDAQ:FLXN) - intelligentinvestor.com.au
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Marquis Who's Who Honors Shomari Hogan, MD, for Expertise in Consulting Services - 24-7 Press Release Newswire
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight - Barchart.com
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Osteoarthritis Therapeutics Market Size [2033] Report - SkyQuest
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide - Baylor College of Medicine Blog Network -
Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - Insightace Analytic
Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire
Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma
Madison Topic FLEXION THERAPEUTICS, INC. | News, Weather, Sports, Breaking News - WMSN
Osteoarthritis Injectables Market Size & Share Report, 2030 - Grand View Research
U.S. Osteoarthritis Injectables Market | Industry Report, 2030 - Grand View Research
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs - GlobeNewswire
Is Osteoarthritis Cure — ARPA-H NITRO — Rocket Fuel Or TNT? - Clinical Leader
Knee Osteoarthritis Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies To Look OutTechfields, Centrexion, Biosplice, Ampio, Paradigm, Grünenthal, Naturecell, MiMedx, TissueTech, Organogenesis - Yahoo Finance
Joint Pain Injections Market Strategic Market Study 2033 - SkyQuest Technology Consulting
Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic - PR Newswire
Global Joint Pain Injections Market Size & Share Revenue Is - GlobeNewswire
Osteoarthritis Therapeutics Market to Register a Steady CAGR of 8.70% Between 20222030 - Digital Journal
Versant Development Fund Iii, L.p. Net Worth (2025) - GuruFocus
Utpal Koppikar named Alphabet health firm Verily CFO - The American Bazaar
Indian American Utpal Koppikar Named CFO of Alphabet Precision Health Company Verily - American Kahani
Verily Appoints Utpal Koppikar as Chief Financial Officer - FinancialContent
Finanzdaten der Flexion Therapeutics, Inc.-Aktie (FLXN)
Es liegen keine Finanzdaten für Flexion Therapeutics, Inc. (FLXN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
8.08%
Kapitalisierung:
|
Volumen (24h):